Latest Healthcare It News

Anatara Lifesciences has raised $1.2 million through a discounted share placement to fund its Anti-Obesity project and explore new opportunities. The capital injection reflects strong institutional support amid ongoing pipeline development.

Radiopharm Theranostics has received a positive safety recommendation to increase the dose of its radiotherapeutic 177Lu-RAD202 in the Phase 1 HEAT trial for HER2-positive advanced solid tumors, signaling promising early results.

Micro-X has completed its first Head CT test bench, marking a key milestone as it begins pivotal imaging trials in Australian hospitals to revolutionize stroke diagnosis.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

Biome Australia Limited has reported a record-breaking $5.94 million in sales revenue for Q1 FY26, surpassing forecasts and accelerating toward its ambitious Vision 27 revenue goals.

Memphasys Limited has revised its FY25 financials to reflect a $1.12 million liability linked to uncertain compliance with R&D tax incentive rules, pending a private tax ruling.

Wellnex Life Limited reported a robust 40.5% revenue increase in FY25, driven by the full-year integration of Pain Away, while margin recovery gains momentum in the second half.

ParagonCare has released its audited FY25 financial results, confirming steady profit while revealing a significant reclassification of debt and ongoing challenges with a major retail pharmacy receivable.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.